Loading…
Please register to continue your trial period!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Uncontrolled cellular proliferation, driven by the dysregulation of cell-cycle machinery and the activation of cyclin-dependent kinases (CDKs), is a defining characteristic of cancer. As a result, agents that target CDKs have been viewed as promising therapeutic options in the treatment of cancer. However, the first-generation Pan-Cyclin-dependent kinase (CDK) inhibitors did not succeed in clinical trials due to their adverse effects and low efficacy. Recently, a new generation of selective CDK4/6 inhibitors, such as [Ribociclib](brain://i_MEkBD1nUKeEgCWtGPQwQ/RibociclibPreclinicalClin…